Tolerance to pirprofen and preliminary efficacy trial in rheumatoid arthritis

Publisher Website
Google Scholar
Abstract
Pirprofen is an anti‐inflammatory drug derived from propionic acid. The compound inhibits the inflammatory response in the paw edema test, the cotton pellet granuloma test, and the adiuvant arthritis model in rats. Animal studies indicated a propensity to cause gastrointestinal ulcerations. Normal human subiects tolerated doses up to 600 mg per day. Occult fecal blood loss was rare. A preliminary efficacy study in 3 patients with definite, active rheumatoid arthritis showed apparent therapeutic benefit in doses of 200 to 400 mg daily. Pirprofen 400 mg per day was therapeutically eqUivalent to indomethacin 100 mg per day in 18 patients with definite, active rheumatoid arthritis in a double‐blind comparison. Adverse effects appeared to be more frequently abdominal in origin during pirprafen and more often central nervous system related during indomethacin. No serious manifestations of toxicity were noted in these studies.

This publication has 0 references indexed in Scilit: